Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2013 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.
Journal Article Blood · January 1, 2026 The progression of multiple myeloma (MM), an incurable malignancy of plasma cells, is often associated with the suppression of ferroptosis, a type of cell death driven by iron-dependent lipid peroxidation. The mechanisms underlying this suppression remain ... Full text Link to item CiteBeta-Arrestin 1 Deficiency Enhances Host Anti-Myeloma Immunity Through T Cell Activation and Checkpoint Modulation.
Journal Article Int J Mol Sci · November 27, 2025 Beta-arrestin 1 (ARRB1) is a multifunctional adaptor protein that regulates diverse signaling pathways beyond its canonical role in G-protein-coupled receptor desensitization. While ARRB1 has been implicated in cancer progression, its role in modulating ho ... Full text Open Access Link to item CiteOptimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation.
Journal Article Adv Sci (Weinh) · November 2025 Human thioredoxin-1 (TRX) is a target-selective disulfide reductase with antioxidant, anti-inflammatory, and regulatory functions that mitigates cellular stresses in various organ systems, providing a compelling rationale for therapeutic use as a broad-spe ... Full text Open Access Link to item CiteRecent Grants
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2025 - 2030Thioredoxin derivatives for radiation mitigation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2030A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator?s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, B
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2025 - 2030View All Grants
Education, Training & Certifications
Shanghai Second Medical University (China) ·
1991
M.D.